StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)

Close on Nov 17, 2026Market cap $2.39MP/E –Yield –

20/20 Biolabs operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$3.33M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.33M–
FY2024Dec 31, 2024-$5.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.24M–
Q1 FY2026Mar 31, 2026-$1.44M–
Q2 FY2025Jun 30, 2025-$845.67K–
Q1 FY2025Mar 31, 2025-$772.18K–

More 20/20 Biolabs figures

See a number that looks wrong?